Resverlogix Corp.

OTC: RVXCF · Healthcare · Biotechnology

Canadian filerHQ Calgary, ABReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 19DQ —GM —SS 53

v0.1 · 35/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ balance-sheet leverage, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$7.9M

Employees

Market cap

$22.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$7.9M-$7.9M2025

Operating income-$5.2M-$5.2M2025

Total assets$7.9M$7.9M2025

Liabilities$96.7M$96.7M2025

Equity-$88.8M-$88.8M2025

Revenue trend

FY2016 – FY2025 · USD

FY16

FY17

FY18

FY19

FY21

FY22

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Resverlogix Corp. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Rubicon Organics Inc.63C Talphera, Inc.46D Rockwell Medical, Inc.60C Retractable Technologies, Inc.57C

Key facts

CEODonald J. McCaffrey

SectorHealthcare

IndustryBiotechnology

HeadquartersCalgary, AB

ExchangeOTC: RVXCF

Employees19

IPO date2009-02-13

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.